BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
For the nine months, revenue was PLN 36.08 million compared to PLN 26.56 million a year ago. Net income was PLN 3.51 million compared to PLN 1.19 million a year ago. Basic earnings per share from continuing operations was PLN 0.05 compared to PLN 0.02 a year ago. Diluted earnings per share from continuing operations was PLN 0.05 compared to PLN 0.02 a year ago.